& BURLINGTON, Mass.–( BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. © 2018 Cable News Network.Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark HoldingsĬontent of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial

Subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLCĬNN. Dow Jones: The Dowīranded indices are proprietary to and are calculated, distributed and marketed by DJI Chicago Mercantile Association: Certain market data is the property of Factset: FactSet Research Systems Inc.2018. Market indices are shown in real time, exceptĭJIA, which is delayed by two minutes. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stock quote data provided by BATS. WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. Given these facts, WeissLaw is concerned whether the proposed acquisition agreement undervalues the Company, whether the Board ran a fair process, and whether all material information related to the proposed acquisition is fully and fairly disclosed. (888) is investigating whether ArQule's Board acted to maximize shareholder value prior to entering into the acquisition agreement. Notably, the Company's stock has an average rating of 'buy.' The deal will also boost Merck's oncology pipeline with ArQule's strategic assets, including its lead pipeline candidate ARQ 531, an oral therapy being tested for the treatment of patients with lymphatic diseases. If you own ARQL shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

Arql website